Literature DB >> 15546888

N-Acetylcysteine ameliorates lithium-induced renal failure in rats.

Shai Efrati1, Michael Averbukh, Sylvia Berman, Leonid Feldman, Victor Dishy, Leonid Kachko, Joshua Weissgarten, Ahuva Golik, Zhan Averbukh.   

Abstract

BACKGROUND: Prolonged lithium treatment may induce progressive deterioration of renal function in humans and experimental animals. N-Acetylcysteine (NAC) has been shown to be effective in the prevention of hypoperfusion and toxin-induced renal failure, but its effect on lithium nephrotoxicity has not been evaluated yet. The purpose of this study was to examine a possible renoprotective effect of NAC against lithium-induced renal failure in a rat model.
METHODS: Moderate renal failure was induced in 40 Sprague-Dawley rats using a 5 week protocol including 3 weeks of lithium chloride administration in the drinking water. The animals were divided randomly into two equal groups receiving either 10 mg/kg NAC or saline by two daily intraperitoneal injections. In week 6, the glomerular filtration rate (GFR) was assessed by 99mTechnetium diethylene triaminepentaacetic acid, and serum creatinine, blood urea nitrogen (BUN) and 24 h urinary protein and osmolarity were measured. Kidneys were excised for pathological evaluation.
RESULTS: At the end of the lithium protocol, the GFR was significantly higher in the NAC-treated group compared with the control group, 0.92+/-0.35 vs 0.56+/-0.25 ml/min/100 g, respectively, P = 0.002. Serum creatinine and BUN were also significantly lower in the NAC-treated group 1.009+/-0.107 vs 1.143+/-0.118 mg/dl, P = 0.001, and 83.9+/-6.8 vs 88.95+/-7.1 mg/dl, P = 0.28, respectively. The percentages of tubular necrosis and tubular lumen obstruction, evaluated by light microscopy, were significantly lower in the NAC-treated group, P = 0.002 and P = 0.007, respectively.
CONCLUSIONS: NAC treatment has a renoprotective effect against lithium-induced renal failure in a rat model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546888     DOI: 10.1093/ndt/gfh573

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  In Vitro and In Vivo Evidence on the Role of Mitochondrial Impairment as a Mechanism of Lithium-Induced Nephrotoxicity.

Authors:  Mohammad Mehdi Ommati; Hossein Niknahad; Omid Farshad; Negar Azarpira; Reza Heidari
Journal:  Biol Trace Elem Res       Date:  2020-07-25       Impact factor: 3.738

Review 2.  N-acetylcysteine -- passe-partout or much ado about nothing?

Authors:  Mirja-Liisa Aitio
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 3.  Molecular mechanisms in lithium-associated renal disease: a systematic review.

Authors:  Soham Rej; Shamira Pira; Victoria Marshe; André Do; Dominique Elie; Karl J Looper; Nathan Herrmann; Daniel J Müller
Journal:  Int Urol Nephrol       Date:  2016-06-29       Impact factor: 2.370

4.  Lipid peroxidation, antioxidant activities and stress protein (HSP72/73, GRP94) expression in kidney and liver of rats under lithium treatment.

Authors:  Riadh Nciri; Mohamed Salah Allagui; Ezzedine Bourogaa; Monji Saoudi; Jean-Claude Murat; Françoise Croute; Abdelfettah Elfeki
Journal:  J Physiol Biochem       Date:  2011-09-27       Impact factor: 4.158

5.  Lithium-induced renal toxicity in rats: protection by a novel antioxidant caffeic acid phenethyl ester.

Authors:  Faruk Oktem; Fehmi Ozguner; Osman Sulak; Seref Olgar; Onur Akturk; H Ramazan Yilmaz; Irfan Altuntas
Journal:  Mol Cell Biochem       Date:  2005-09       Impact factor: 3.396

Review 6.  N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence.

Authors:  Hesamoddin Hosseinjani; Azadeh Moghaddas; Hossein Khalili
Journal:  Eur J Clin Pharmacol       Date:  2013-03-19       Impact factor: 2.953

7.  Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial.

Authors:  Michael Berk; Olivia M Dean; Sue M Cotton; Clarissa S Gama; Flavio Kapczinski; Brisa Fernandes; Kristy Kohlmann; Susan Jeavons; Karen Hewitt; Kirsteen Moss; Christine Allwang; Ian Schapkaitz; Heidi Cobb; Ashley I Bush; Seetal Dodd; Gin S Malhi
Journal:  BMC Med       Date:  2012-08-14       Impact factor: 8.775

8.  Findings from a pilot open-label trial of N-acetylcysteine for the treatment of pediatric mania and hypomania.

Authors:  Janet Wozniak; Maura DiSalvo; Abigail Farrell; Carrie Vaudreuil; Mai Uchida; T Atilla Ceranoglu; Gagan Joshi; Emmaline Cook; Stephen V Faraone; Joseph Biederman
Journal:  BMC Psychiatry       Date:  2022-05-03       Impact factor: 4.144

9.  New insights into negative effects of lithium on sea urchin Paracentrotus lividus embryos.

Authors:  Nadia Ruocco; Maria Costantini; Luigia Santella
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

10.  N-acetylcysteine suppresses colistimethate sodium-induced nephrotoxicity via activation of SOD2, eNOS, and MMP3 protein expressions.

Authors:  Bahadir Ceylan; Mehmet Ozansoy; Ülkan Kılıç; Yasemin Yozgat; Çilem Ercan; Pelin Yıldız; Turan Aslan
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.